Monday, December 19, 2016

BRIEF-MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis

* MediciNova announces phase 2b trial of MN-166 (ibudilast)

in progressive MS will continue as planned following DSMB review

of interim efficacy analysis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)